Skip to content

Allotment

Gaudium IVF & Women Health Ltd.

Gaudium IVF IPO is a book-built issue comprising 2.09 crore equity shares, which includes a fresh issue of 1.14 crore shares and an offer for sale (OFS) of 0.95 crore shares.

The IPO will open for subscription on February 20, 2026, and close on February 24, 2026. The basis of allotment is expected to be finalized on February 25, 2026. The shares are proposed to be listed on the BSE and the National Stock Exchange of India, with a tentative listing date of February 27, 2026.

The price band for the Gaudium IVF IPO has been fixed at ₹[.] to ₹[.] per share.

Sarthi Capital Advisors Pvt. Ltd. is acting as the book-running lead manager to the issue, while Bigshare Services Pvt. Ltd. has been appointed as the registrar.

Gaudium IVF & Women Health Ltd. IPO & Charts
₹79

0%

Open

₹79

HIgh - Low

₹79

Previous Close

₹79

Total Traded Value

0

52 Weeks High

₹79

52 Weeks Low

₹79

Updates On

Feb 15, 2026

IPO. Open

Feb 20, 2026

IPO. Close

Feb 24, 2026

IPO. Price

₹79

IPO Market price

₹575.02 Cr

IPO Details

IPO Date 27 Feb
IPO Listing Date 27 Feb
IPO Face Value ₹5.00 per share
IPO Price Range ₹79
IPO Issue Size 2,08,86,200 shares
IPO Sale Type Fresh Capital & OFS
Employee Discount -
IPO Issue Type Bookbuilding IPO
IPO Listing BSE, NSE Platform
Share Holding Pre Issue 6,13,94,384 shares

IPO Timeline

IPO Open Date 20 Feb
IPO Close Date 24 Feb
IPO Allotment (Tentative) 25 Feb
Refunds 25 Feb
Credit to Demat Account 26 Feb
IPO Listing Date 27 Feb

IPO Reservation

Category Offer
QIB Shares Offered 1,04,43,100
NII (HNI) Shares Offered 31,32,930
Retail Shares Offered 73,10,170

IPO Lot Size

Investors can bid for a minimum of 189 shares and in multiples thereafter.

Application Lots Share Amount
Retail (Min) 1 189 ₹14,931
Retail (Max) 13 2,457 ₹1,94,103
S-HNI (Min) 14 2,646 ₹2,09,034
S-HNI (Max) 66 12,474 ₹9,85,446
B-HNI (Min) 67 12,663 ₹10,00,377
About Company

Incorporated in March 2015, Gaudium IVF and Women Health Limited is engaged in providing In Vitro Fertilization (IVF) treatments across India. The company has expanded its footprint across multiple states through a hub-and-spoke model.

The company operates more than 30 centres, comprising seven hubs and 28 spokes. It has also formed strategic alliances with infertility specialists (spokes) to promote awareness and accessibility of Assisted Reproductive Technology (ART) and IVF treatments.

Gaudium IVF serves patients not only from India but also from international markets such as Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.

Its centres are located in major cities, including two in Delhi (Janakpuri and Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, ensuring presence across key urban locations.

The company offers a wide range of specialized fertility treatments, including IVF, Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. Its services address various infertility challenges affecting both men and women. In addition, it provides comprehensive gynaecological care for conditions such as PCOD/PCOS and endometriosis, along with high-risk pregnancy management for women with complex fertility histories or underlying medical conditions.

The facilities also offer an extensive range of male infertility treatments, including advanced sperm retrieval procedures.

Competitive Strengths

  • Patient-centric approach focused on personalized treatment and care
  • Experienced and expert medical team
  • Use of next-generation INTEGRA Ti labs for ICSI procedures
  • Highly technical ultrasound-guided (USG) services
  • Established central hubs in prime urban locations, including Mumbai, Bangalore, Delhi NCR, and Patna
  • Asset-light business model, enabling scalable expansion

Company Financials (Consolidated)

Assets 106.62 88.51 51.01
Total Income 49.75 70.96 48.15
Profit After Tax 12.51 19.13 10.32
EBITDA 18.95 28.63 19.27
NET Worth 58.85 46.3 26.99
Reserves and Surplus 28.16 15.6 26
Total Borrowing 22.51 18.93 15.73

Key Performance Indicator (KPI)

ROE 21.25%
ROCE 21.03%
Debt/Equity 0.38
RoNW 21.34%
PAT Margin 25.14%
EBITDA Margin 38.29%
Price to Book Value
IPO Objective

IPO Objects of the Issue

S.No. Objects of the ipo Resources Detail IPO Amount
1 Funding capital expenditure requirements for the purchase of equipment/machineries 50
2 To meet out the expenses of Working Capital Requirement -
3 To meet out the General Corporate Purposes; -
4 Offer for Sale (OFS) -

Contact Details

Gaudium IVF & Women Health Ltd. Address
B1/51,
Janak Puri,
B-1,
New Delhi, New Delhi, 110058
011-4885 8585
compliance@gaudiumivfcentre.com
https://www.gaudiumivfcentre.com/

Detail Registrar

IPO Registrar
Bigshare Services Pvt.Ltd.

+91-22-6263 8200
ipo@bigshareonline.com
https://ipo.bigshareonline.com/IPO_Status.html

FAQ

The Gaudium IVF IPO will open on February 20, 2026, and close on February 24, 2026, giving investors a five-day window to apply for shares.

The IPO comprises 2.09 crore equity shares, including a fresh issue of 1.14 crore shares and an Offer for Sale (OFS) of 0.95 crore shares.

The shares are proposed to be listed on BSE and NSE with a tentative listing date of February 27, 2026, allowing investors to trade publicly.

Sarthi Capital Advisors Pvt. Ltd. is the book-running lead manager, while Bigshare Services Pvt. Ltd. is the registrar for allotment and IPO-related queries.

As of March 31, 2025, the company has a PAT margin of 26.96%, EBITDA margin of 40.48%, ROE of 41.31%, and a healthy Debt-to-Equity ratio of 0.41 post-IPO.

The company operates 30+ centres across India, providing IVF, ICSI, IUI, ovulation induction, male infertility treatments, and gynaecology care. It uses advanced INTEGRA Ti labs, ultrasound-guided procedures, and an asset-light model enabling scalable expansion.

Compare:

Back To Top